KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EPS (Weighted Average and Diluted) (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 16 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.43 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 116.67% year-over-year to -$1.43; the TTM value through Dec 2025 reached -$2.38, up 21.71%, while the annual FY2025 figure was -$2.38, 260.61% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.43 in Q4 2025 per IONS's latest filing, down from -$0.8 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.41 in Q4 2021 and bottomed at -$1.43 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.51, with a median of -$0.62 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 1000.0% in 2024, then surged 273.33% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.41 in 2021, then tumbled by 126.24% to -$0.37 in 2022, then soared by 83.78% to -$0.06 in 2023, then tumbled by 1000.0% to -$0.66 in 2024, then crashed by 116.67% to -$1.43 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.43 in Q4 2025, -$0.8 in Q3 2025, and $0.78 in Q2 2025.